Neogen Co. (NASDAQ:NEOG) CFO David H. Naemura Purchases 14,800 Shares

Neogen Co. (NASDAQ:NEOG) CFO David H. Naemura purchased 14,800 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $11.11 per share, with a total value of $164,428.00. Following the transaction, the chief financial officer now directly owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. This represents a 31.74 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Neogen Stock Performance

Shares of NEOG opened at $11.60 on Friday. The stock has a market capitalization of $2.51 billion, a PE ratio of -5.30 and a beta of 1.23. The business’s fifty day moving average price is $13.24 and its 200 day moving average price is $14.97. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.41 and a quick ratio of 2.79. Neogen Co. has a 12-month low of $10.72 and a 12-month high of $18.58.

Neogen (NASDAQ:NEOG) last issued its earnings results on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a negative net margin of 2.58% and a positive return on equity of 2.80%. The company had revenue of $231.30 million for the quarter, compared to analysts’ expectations of $227.16 million. During the same period in the prior year, the company earned $0.11 earnings per share. The firm’s revenue was up .7% compared to the same quarter last year. Equities research analysts forecast that Neogen Co. will post 0.5 EPS for the current year.

Wall Street Analyst Weigh In

NEOG has been the subject of several recent analyst reports. Guggenheim began coverage on shares of Neogen in a report on Thursday, December 19th. They set a “buy” rating and a $15.00 price objective for the company. StockNews.com raised Neogen to a “sell” rating in a report on Monday, September 30th.

Hedge Funds Weigh In On Neogen

Large investors have recently bought and sold shares of the business. Select Equity Group L.P. grew its holdings in shares of Neogen by 23.1% during the second quarter. Select Equity Group L.P. now owns 15,530,439 shares of the company’s stock valued at $242,741,000 after purchasing an additional 2,914,893 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Neogen by 24.5% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 8,706,224 shares of the company’s stock worth $146,352,000 after purchasing an additional 1,711,238 shares during the last quarter. State Street Corp boosted its position in Neogen by 3.1% during the 3rd quarter. State Street Corp now owns 7,932,192 shares of the company’s stock valued at $133,340,000 after purchasing an additional 236,762 shares during the period. Bamco Inc. NY grew its stake in Neogen by 1.4% during the 3rd quarter. Bamco Inc. NY now owns 7,303,115 shares of the company’s stock worth $122,765,000 after buying an additional 98,067 shares during the last quarter. Finally, Champlain Investment Partners LLC increased its position in Neogen by 10.7% in the third quarter. Champlain Investment Partners LLC now owns 7,110,530 shares of the company’s stock worth $119,528,000 after buying an additional 690,029 shares during the period. Institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.